company background image
PAIO.F logo

Paion OTCPK:PAIO.F Stock Report

Last Price

US$0.02

Market Cap

US$46.3k

7D

0%

1Y

n/a

Updated

26 Nov, 2024

Data

Company Financials

PAIO.F Stock Overview

A specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. More details

PAIO.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Paion AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paion
Historical stock prices
Current Share Price€0.02
52 Week High€0.07
52 Week Low€0.02
Beta1.61
11 Month Change0%
3 Month Change0%
1 Year Changen/a
33 Year Change-99.90%
5 Year Change-99.91%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Shareholder Returns

PAIO.FUS BiotechsUS Market
7D0%4.0%2.2%
1Yn/a18.3%32.6%

Return vs Industry: Insufficient data to determine how PAIO.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PAIO.F performed against the US Market.

Price Volatility

Is PAIO.F's price volatile compared to industry and market?
PAIO.F volatility
PAIO.F Average Weekly Movementn/a
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: PAIO.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PAIO.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200064Gregor Siebertwww.paion.com

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Paion AG Fundamentals Summary

How do Paion's earnings and revenue compare to its market cap?
PAIO.F fundamental statistics
Market capUS$46.33k
Earnings (TTM)-US$20.80m
Revenue (TTM)US$15.51m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAIO.F income statement (TTM)
Revenue€14.81m
Cost of Revenue€6.35m
Gross Profit€8.46m
Other Expenses€28.32m
Earnings-€19.86m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.78
Gross Margin57.15%
Net Profit Margin-134.12%
Debt/Equity Ratio-675.5%

How did PAIO.F perform over the long term?

See historical performance and comparison